Evaluation shows safety and effectiveness for the management of localized prostate cancer
WEDNESDAY, June 1, 2022 (HealthDay News) — The KangDuo Surgical Robot-01 (KD-SR-01) system is safe and effective for robot-assisted radical prostatectomy, according to a study published online May 18 in The Journal of Urology.
Shubo Fan, from Peking University First Hospital in Beijing, and colleagues assessed the feasibility, safety, and effectiveness of the KD-SR-01 system for robot-assisted radical prostatectomy (RARP). Data from 16 RARP procedures with the KD-SR-01 system, all performed by one surgeon, were analyzed.
The researchers reported that all cases were completed without conversion to traditional RARP, laparoscopic surgery, or open surgery. The median docking time was 5.9 minutes, console time was 87 minutes, and urethrovesical anastomosis time was 14.4 minutes. Median blood loss was estimated to be 50 mL, with no patients requiring intraoperative transfusion. Five days was the median postoperative hospital stay. Four patients (25 percent) had a positive surgical margin. At one month postsurgery, there were no biochemical recurrences reported and the continence rate was 87.5 percent. There were no severe intraoperative or postoperative complications observed, and the surgeon reported a high comfort level.
“Although the price has not yet been determined, the emergence of new robotic surgery systems lowers the cost of robotic surgery, which could benefit more patients,” the authors write.
One author is the cofounder and stock owner of Suzhou KangDuo Robot Co.
Adenotonsillectomy Tied to Increase in Respiratory Tract Infections in Children
Robotic Arm-Assisted TKR Offers Similar Outcome to Conventional TKR
Preoperative Chemo + Immunotherapy Combo Shrinks Head, Neck Cancer Tumors
Risk for Prostate Cancer Elevated With Higher Ultraprocessed Food Intake
Rates of Active Surveillance for Low-Risk Prostate Cancer High for Veterans
Achieving PSA <0.2 ng/mL Improves Survival in Metastatic Castration-Sensitive Prostate Cancer
Multivariable Risk Score Beneficial for Identifying Clinically Significant Prostate Cancer